The lining of your small intestine is a single layer of epithelial cells held together by proteins called tight junctions. When those junctions loosen (a condition researchers call increased intestinal permeability, or colloquially ‘leaky gut’) bacterial fragments, undigested proteins, and other luminal contents can cross into circulation and trigger systemic inflammation. This is not a fringe concept; it appears in peer-reviewed gastroenterology literature as a measurable physiological state associated with a range of metabolic and inflammatory conditions.
Akkermansia muciniphila, a gram-negative bacterium that lives in the mucus layer lining your gut, has attracted substantial scientific interest as one organism that may help keep those tight junctions intact. It was found at more than 1% of faecal cells in one study of human samples, but abundance varies widely between people, and it has been reported to be lower in obesity and type 2 diabetes. Findings on age are mixed [5][6][7][8][9][10]. Understanding what this bacterium does, and what the evidence actually supports, requires looking carefully at proposed mechanisms, human trial data, and the genuine gaps that remain.
Key Takeaways
- Akkermansia muciniphila is a mucus-layer bacterium proposed to support intestinal barrier integrity through mucin turnover, tight-junction protein upregulation via Amuc_1100 signaling, and short-chain fatty acid production.
- Lower Akkermansia abundance has been reported in people with type 2 diabetes and obesity, but these are observational findings that EFSA noted may reflect reverse causation [8][11][12][7][13].
- A small 2019 pilot found that pasteurized Akkermansia improved insulin sensitivity in overweight or obese insulin-resistant adults, but a larger 142-adult trial in adults with metabolic syndrome did not meet its primary endpoint, and larger, well-powered trials with permeability as a primary endpoint are still needed [14][15].
- Polyphenol-rich foods, prebiotic fiber, caloric balance, aerobic exercise, and limiting antibiotic overuse are practical lifestyle levers for supporting Akkermansia abundance.
- Akkermansia supplements are not FDA-approved treatments; immunocompromised individuals and those with active inflammatory bowel disease should consult a physician before use.
What 'Leaky Gut' Actually Means
Intestinal permeability refers to how selectively the gut epithelium controls what passes from the lumen into underlying tissue and the bloodstream. Under normal conditions, tight-junction proteins (including occludin, claudins, and zonula occludens proteins) form a regulated seal that permits water and nutrients to cross while excluding most bacteria and large molecules.
When this seal is compromised, lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, can enter systemic circulation. Elevated circulating LPS has been associated with low-grade endotoxemia, a state of chronic, sub-clinical inflammation linked to insulin resistance, non-alcoholic fatty liver disease, and cardiovascular risk markers. Gut dysbiosis, an imbalance in the composition or function of the gut microbial community, is one recognized contributor to increased permeability, and dysbiotic states have been implicated in the progression of serious disease [1].
It is important to note that ‘leaky gut’ is not a single diagnosis with a single cause. Factors including diet, alcohol, chronic stress, non-steroidal anti-inflammatory drugs, and infections can all increase intestinal permeability by distinct mechanisms.
How Akkermansia muciniphila Interacts with the Gut Barrier
Akkermansia’s primary ecological role is degrading the mucin glycoproteins that form the mucus layer coating the gut epithelium. This might sound counterproductive, consuming mucin sounds like it would thin the barrier, but the relationship is more nuanced. Akkermansia’s activity appears to stimulate goblet cells to produce new mucin, effectively turning over and renewing the mucus layer rather than depleting it. In mice, a high-fat diet thinned the colonic mucus layer and depleted Akkermansia, and in one study heat-killed cells did not improve mucus layer thickness, so results depend on the form given [16][17].
Research note: EFSA said that, even at very low live-cell exposure from the pasteurised product, a possible adverse impact on gut barrier integrity and microbiota balance in susceptible people could not be ruled out, so it asked for a near-zero viable-cell specification [13].
Beyond mucin metabolism, researchers have identified a specific outer-membrane protein from Akkermansia called Amuc_1100. In preclinical studies, Amuc_1100 interacts with Toll-like receptor 2 on intestinal epithelial cells and appears to promote the expression of tight-junction proteins, including claudin-3. This mechanism is notable because it suggests that even pasteurized or non-viable Akkermansia preparations may retain some barrier-supportive signaling capacity: a finding that has practical implications for supplement formulation and safety.
Akkermansia also produces short-chain fatty acids and propionate during mucin fermentation. Propionate serves as an energy source for colonocytes (the epithelial cells lining the colon) and has been associated with reduced inflammatory signaling in intestinal tissue.
Evidence from Human Trials: What Has Been Studied
The human evidence base for Akkermansia and intestinal permeability specifically is still developing. The most-cited human intervention study to date was a 2019 pilot that enrolled 40 overweight or obese insulin-resistant adults (32 completed) and gave them live or pasteurized Akkermansia muciniphila daily for three months [18]. Compared with placebo, the pasteurized form improved insulin sensitivity by 28.62%, lowered insulinemia by 34.08% and plasma total cholesterol by 8.68%, while the weight change did not reach conventional significance. The live preparation did not significantly improve insulin sensitivity [18][14]. Blood markers of liver dysfunction and inflammation were also reduced after supplementation, and the overall gut microbiome structure was unaffected [18].
This is promising, but the study was small and its main results were metabolic rather than gut-barrier measures. A later trial of 142 adults with metabolic syndrome, using 30 billion pasteurized cells daily, did not change its primary endpoint of insulin sensitivity, and its authors include employees and a co-founder of the maker [15]. Larger, longer trials with intestinal permeability as a pre-specified endpoint are needed before firm conclusions can be drawn. At present, no human study has established that Akkermansia supplementation definitively closes a clinically leaky gut in people with diagnosed increased permeability.
Human trials have also explored Akkermansia abundance in the context of inflammatory and metabolic conditions. Reduced Akkermansia abundance has been reported in some studies of people with obesity, type 2 diabetes and active ulcerative colitis, but a biopsy study found no overall difference between healthy controls, ulcerative colitis and Crohn’s disease, and its role in IBD and colorectal cancer is described as inconclusive [7][8][19][20][21]. Whether low Akkermansia is a cause or a consequence of these conditions, or both, remains an active research question.
Diet, Lifestyle, and Akkermansia Abundance
Akkermansia abundance appears to be responsive to diet. Cranberry extract and green tea extract raised Akkermansia in mice, and a systematic review of dietary trials reported higher abundance with caloric restriction and with supplements including pomegranate extract and inulin, although the review says the evidence is not clear and only five of 29 trials examined Akkermansia alone. Inulin did not raise it in a pilot of adults with type 1 diabetes [22][23][24][25]. The proposed mechanism is that polyphenols and certain fermentable fibers preferentially support the mucus-layer environment in which Akkermansia thrives.
Conversely, high-fat, high-sugar Western diets have been consistently associated with reduced Akkermansia abundance in animal models, alongside increased intestinal permeability and elevated circulating endotoxins. Chronic restraint stress lowered Akkermansia in mice, and antibiotic use has been associated with low Akkermansia in cancer patients. Whether diet and lifestyle changes raise Akkermansia enough to change health outcomes has not been shown in trials [26][27][24].
A review says moderate exercise enriches Akkermansia, but most of that evidence comes from animal or small human studies and causality is unclear. In 70 postmenopausal women with type 2 diabetes, a 12-week home exercise program raised Akkermansia [28][29]. This convergence of diet, exercise, and microbial composition underscores how interconnected gut health is with general lifestyle factors.
Supplement Formulations: Live vs. Pasteurized Akkermansia
A practical consideration when evaluating Akkermansia products is the distinction between live and pasteurized formulations. Live probiotic bacteria face the challenge of surviving gastric acid, bile, and the transit through the small intestine to reach the colon. Pasteurization kills the bacteria but may preserve the Amuc_1100 outer-membrane protein and potentially other bioactive components. In the 2019 pilot only the pasteurized arm improved insulin sensitivity, but mouse studies disagree about which form works better: one found viable cells were needed, while others found pasteurized cells more effective [14][17][30][31].
As of this writing, Akkermansia muciniphila supplements are not approved by the U.S. Food and Drug Administration to treat, cure, or prevent any disease. The regulatory status of these products varies by country. Most commercially available preparations are classified as dietary supplements or novel foods, with corresponding limits on the health claims that manufacturers can legally make.
Refrigerated storage is typically required for live preparations to maintain viable counts. Pasteurized formulations are generally more shelf-stable. Neither form should be considered a substitute for evidence-based medical treatment of diagnosed gastrointestinal conditions.
Extracellular Vesicles as Long-Range Barrier Signals
Bacteria continuously shed nanoscale membrane-derived particles called extracellular vesicles (EVs). Because these vesicles are far smaller than the parent bacterium, they can traverse the mucus layer and reach the epithelial surface even when live bacteria do not. A. muciniphila-derived EVs have been identified as biologically active signaling molecules with measurable effects on the gut epithelium.
In a 2018 experimental study, A. muciniphila EVs were shown to influence gut permeability through the specific regulation of tight-junction proteins [2]. The vesicles promoted expression of junction-associated proteins in exposed epithelial cells, suggesting that A. muciniphila may exert some of its barrier-related effects without requiring direct cell-to-cell contact. This finding is particularly relevant to the ongoing evaluation of pasteurized and EV-enriched preparations of the bacterium, where live bacteria are absent but membrane-derived fractions remain intact.
Heat Stress, Caco-2 Cells, and HSP27 Modulation
A 2023 in vitro investigation examined whether A. muciniphila could restore intestinal barrier function impaired by heat stress. Using the well-established Caco-2 human intestinal epithelial cell model, researchers subjected cells to heat stress and then assessed permeability and tight-junction integrity. Addition of A. muciniphila was associated with improved barrier function, and the proposed mechanism involved modulation of heat-shock protein 27 (HSP27) [3].
HSP27, when phosphorylated under stress conditions, can reorganize the actin cytoskeleton and displace tight-junction proteins from their normal membrane-associated positions. By attenuating this aberrant HSP27 activity, A. muciniphila treatment appeared to help preserve the structural organization of claudin and occludin at cell-cell contacts [3]. These are cell-culture findings and cannot be directly extrapolated to human outcomes without further clinical investigation.
Amuc_1100: The Outer-Membrane Protein and Epithelial Repair
One of the most studied molecular actors in A. muciniphila barrier research is Amuc_1100, a heat-stable outer-membrane protein that has been investigated both as part of the intact bacterium and in isolated form. Because it retains activity after pasteurization, Amuc_1100 has attracted particular interest as a potential active component of non-live formulations.
A 2023 study found that A. muciniphila and its membrane protein reduced intestinal inflammatory stress and promoted epithelial wound healing. The proposed signaling pathway involved activation of CREBH, a liver-enriched transcription factor also expressed in the intestine that regulates metabolic and inflammatory gene programs, along with modulation of microRNAs miR-143 and miR-145, which participate in cytoskeletal organization and epithelial cell differentiation [4]. This mechanistic complexity suggests that A. muciniphila’s barrier-supportive effects may involve coordinated transcriptional regulation of epithelial repair rather than simple upregulation of a single tight-junction protein.
Limitations of Current Evidence and What Research Still Needs to Establish
It is worth being direct about what the evidence does not yet show. The bulk of mechanistic data on Akkermansia and tight-junction function comes from cell culture and rodent studies. Translation from mouse models to human outcomes is notoriously inconsistent in gut microbiome research. Human trials are few, mostly short-term, small in sample size, and not always consistent across populations.
The causal direction of the association between low Akkermansia and increased permeability has not been conclusively established in humans. It is possible that gut barrier disruption reduces the mucosal habitat Akkermansia requires, leading to a secondary decline in abundance, meaning low Akkermansia could be a marker of poor barrier health rather than a primary driver of it.
Not every mouse result is protective. In mice lacking the Il10 gene, A. muciniphila alone was enough to promote intestinal inflammation, and in another mouse test, live or pasteurized Akkermansia given before DSS colitis did not significantly reduce inflammatory markers [32][33].
Long-term safety data on Akkermansia supplementation are also limited. For most healthy adults, the available evidence suggests good tolerability, but individuals with inflammatory bowel disease, compromised immune systems, or those taking immunosuppressive medications face theoretical risks with any live bacterial supplement, and the specific safety profile of Akkermansia in these populations is not fully characterized. Consulting a gastroenterologist or physician before starting supplementation is warranted for these groups.
đ Where to Buy Akkermansia muciniphila
- Pendulum Akkermansia
delayed-release capsules, 100M AFU: Live A. muciniphila strain (WB-STR-0001); single-strain with chicory inulin, third-party tested. - Codeage Akkermansia Muciniphila
capsules, 100M AFU, 90 ct: Lower-cost Akkermansia plus chicory inulin synbiotic; 3-month supply, gluten-free. - Double Wood Akkermansia Probiotic + Postbiotic
capsules, per label: Budget Akkermansia option marketed around GLP-1 and postbiotic support.
As an Amazon Associate we earn from qualifying purchases. Akkermansia is a live, oxygen-sensitive strain: choose a delayed-release, third-party-tested product with a stated live AFU count.
A Note on the Evidence
Research on Akkermansia muciniphila and intestinal permeability is active but still early: most mechanistic evidence comes from preclinical models, and the few human trials to date are small and short-term. Akkermansia supplements are not approved by the FDA to treat, cure, or prevent any disease; individuals who are immunocompromised, taking immunosuppressive medications, pregnant, or living with active inflammatory bowel disease should consult a qualified healthcare provider before use. This article is informational and does not constitute medical advice.
Frequently Asked Questions
What is intestinal permeability and why does it matter?
Intestinal permeability describes how well the gut epithelial lining controls what passes from the intestinal lumen into the body. When tight-junction proteins weaken, bacterial components such as lipopolysaccharide can enter circulation, triggering low-grade systemic inflammation. Dysbiosis-driven barrier dysfunction has been studied in connection with metabolic, inflammatory, and hepatic disease pathways [1].
How does Akkermansia muciniphila support tight junctions?
Akkermansia’s outer-membrane protein Amuc_1100 appears to interact with Toll-like receptor 2 on intestinal epithelial cells, stimulating expression of tight-junction proteins including claudin-3. Separately, its mucin-degrading activity is thought to stimulate goblet-cell mucin renewal, maintaining the protective mucus layer. These mechanisms are primarily characterized in preclinical research and cell studies.
Is pasteurized Akkermansia effective, or does it need to be live?
In a 2019 pilot in overweight or obese insulin-resistant adults, the pasteurized form improved insulin sensitivity versus placebo while the live preparation did not significantly do so. Mouse studies disagree about which form works better [14][17][30]. Pasteurized formulations are also more shelf-stable and may reduce theoretical risks associated with live organisms in vulnerable individuals, though the evidence base is still early.
What foods or habits increase Akkermansia in the gut?
Cranberry and green tea extracts raised Akkermansia in mice, and a systematic review of dietary trials reported higher abundance with caloric restriction and with supplements including pomegranate extract and inulin, though it calls the evidence unclear. Exercise evidence is mostly from animals or small human studies. In mice, a high-fat diet depleted Akkermansia [22][23][24][28][16].
Who should not take Akkermansia supplements without medical supervision?
Individuals who are immunocompromised, undergoing immunosuppressive therapy (such as after organ transplant or for autoimmune conditions), or living with active inflammatory bowel disease face theoretical risks from live bacterial supplements. The specific safety profile of Akkermansia in these populations is not fully established, and a physician or gastroenterologist should be consulted before use.
Can Akkermansia supplements fix a leaky gut?
No supplement has been proven to ‘fix’ increased intestinal permeability as a standalone intervention. Akkermansia research is promising and mechanistically plausible, but human trial evidence specifically targeting gut barrier outcomes is limited and not yet definitive. Akkermansia supplements are not FDA-approved to treat any condition, and increased intestinal permeability with clinical consequences warrants evaluation by a healthcare provider.
References
- Ismaiel A et al. From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma. Frontiers in cellular and infection microbiology (2026). PMID 42345020
- Chelakkot C et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions. Experimental & molecular medicine (2018). PMID 29472701
- Peng M et al. Akkermansia muciniphila improves heat stress-impaired intestinal barrier function by modulating HSP27 in Caco-2Â cells. Microbial pathogenesis (2023). PMID 36796737
- Wade H et al. Akkermansia muciniphila and its membrane protein ameliorates intestinal inflammatory stress and promotes epithelial wound healing via CREBH and miR-143/145. Journal of biomedical science (2023). PMID 37287024
- Derrien M et al. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Applied and environmental microbiology (2008). PMID 18083887
- van Passel MW et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PloS one (2011). PMID 21390229
- Maria Carlota Dao et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut (2015). PMID 26100928
- ChingâTang Shih et al. Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. Microorganisms (2020). PMID 32899513
- Elena Biagi et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. PLoS ONE (2010). PMID 20498852
- Wang Fang et al. Gut Microbiota Community and Its Assembly Associated with Age and Diet in Chinese Centenarians. Journal of Microbiology and Biotechnology (2015). PMID 25839332
- Saiedi E et al. Comparative analysis of gut microbiota composition in the fecal samples from type 2 diabetes mellitus patients and healthy individuals: a case control study. Iranian journal of microbiology (2025). PMID 41510046
- Zhang Z et al. Acylated Ghrelin Mediates the Link Between Akkermansia Abundance and Insulin Resistance in Type 2 Diabetes. Journal of diabetes research (2025). PMID 40799671
- European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes (2026). PMID 42343233
- Liang X et al. Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice. Nature microbiology (2026). PMID 42271159
- Amandine Everard et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences (2013). PMID 23671105
- Depommier C et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature medicine (2019). PMID 31263284
- Helen Earley et al. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis. Scientific Reports (2019). PMID 31666581
- Mireia LĂłpezâSiles et al. Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects. Frontiers in Cellular and Infection Microbiology (2018). PMID 30245977
- Zhen-Yang Gu et al. Akkermansia muciniphila in inflammatory bowel disease and colorectal cancer. Chinese Medical Journal (2021). PMID 34711719
- Fernando F. AnhĂȘ et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut (2014). PMID 25080446
- Gurley BJ et al. Decaffeinated Green Tea Extract Does Not Elicit Hepatotoxic Effects and Modulates the Gut Microbiome in Lean B6C3Fâ Mice. Nutrients (2019). PMID 30987244
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Ojetti V et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences (2026). PMID 41636295
- Chen T et al. Akkermansia muciniphila Protects Against Psychological Disorder-Induced Gut Microbiota-Mediated Colonic Mucosal Barrier Damage and Aggravation of Colitis. Frontiers in cellular and infection microbiology (2021). PMID 34722332
- Vancheswaran Gopalakrishnan et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2017). PMID 29097493
- Yu M et al. Effects of anti-aging diets and exercise on age-related musculoskeletal diseases via gut microbiota modulation. Annals of medicine (2026). PMID 42773801
- Vahed A et al. Effects of home-based exercise training on gut microbiota and possible relations with cognitive function and metabolic health in postmenopausal women with type 2 diabetes mellitus: a randomized control trial. Diabetes research and clinical practice (2025). PMID 41109629
- Fatemeh Ashrafian et al. Comparative effects of alive and pasteurized Akkermansia muciniphila on normal diet-fed mice. Scientific Reports (2021). PMID 34504116
- Fatemeh Ashrafian et al. Extracellular vesicles and pasteurized cells derived from Akkermansia muciniphila protect against high-fat induced obesity in mice. Microbial Cell Factories (2021). PMID 34863163
- Sergey S. Seregin et al. NLRP6 Protects Il10 Mice from Colitis by Limiting Colonization of Akkermansia muciniphila. Cell Reports (2017). PMID 28445725
- Grondin JA et al. Akkermansia muciniphila supplementation alters inflammatory profiles across diverse models of colitis. Scientific reports (2026). PMID 42380569
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
